GALT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

GALT ▲ +15.21% at T+5d

LONG call ✓ call won +15.21% · α vs SPY +14.24% · entry $2.17 → $2.50

Next anchor: T+20d in 5d

Currently $2.41 · +11.06% from $2.17 entry

Entry anchored
May 14, 03:59 PM ET
via Databento tick

T+1d

+0.92%

call +0.92% · α +0.98%

$2.19

settled 23d ago

T+5d

+15.21%

call +15.21% · α +14.24%

$2.50

settled 19d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Galectin Therapeutics reported Q1 2026 EPS of -$0.08, missing consensus of -$0.06 (-33.3% miss), but highlighted positive clinical data from its NAVIGATE trial and upcoming catalysts including EASL presentations and an FDA Type-C meeting. Despite the EPS miss, the clinical progress and upcoming milestones are the primary drivers for the stock.

Actionable Insight

Monitor EASL data presentations (May 28-30) and the FDA Type-C meeting outcome; positive results could significantly de-risk belapectin and drive upside.

Key Facts

Q1 2026 EPS -$0.08 vs consensus -$0.06 (33.3% miss)
Cash and equivalents of $14.1M as of March 31, 2026, plus $10M available line of credit
Positive belapectin NAVIGATE data: statistically significant reduction in liver stiffness at Weeks 26, 52, and 78
Upcoming catalysts: EASL presentations (May 28-30, 2026) and FDA Type-C meeting in Q2 2026

Financial Impact

EPS miss of $0.02 per share, net loss of $5.1M

epsnet losscash position

Risk Factors

Clinical trial and regulatory risk for belapectin
EPS miss reflects ongoing R&D spending; dilution risk via line of credit

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295804

4 reports for GALT

T+1T+5T+20T+60

Filters

Reports for GALT — sortable, filterable
	Type				Now
May 15, 2026 25d ago	Press Release BULLISH ★ 6/10	$2.17 $2.50	▲ +15.21%	▲ +14.24%	$2.41 (+11.06%)
May 15, 2026 25d ago	8-K NEUTRAL ★ 5/10	$2.17 $2.50	▲ +15.21%	▲ +14.24%	$2.41 (+11.06%)
Apr 13, 2026 8w ago	EFFECT NEUTRAL ★ 3/10	$2.35 $2.29	▼ −2.55%	▼ −5.85%	$2.41 (+2.55%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$2.79 $2.22	▼ −20.43%	▼ −24.37%	$2.41 (−13.62%)

US Market Status

Market Closed — Opens Thu (10h 6m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access